Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines. 22330138 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Chromatin regulators ANCCA and EZH2 are overexpressed in prostate cancer and play crucial roles in androgen-stimulated and castration-refractory prostate tumor growth and survival. 23038103 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Further, the results implicate EZH2-driven mechanisms by which Myc may stimulate prostate tumor initiation and disease progression. 21941025 2012
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells. 21903722 2012
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Findings from this study suggest that AI prostate tumors are more dependent on EZH2 expression than AD tumors. 20087897 2010
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 PosttranslationalModification group LHGDN Expression changes in EZH2 are associated with DNA methylation in prostate cancer. 18637271 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN EZH2 may regulate actin polymerization dynamics and thereby promote prostate cancer cell motility and invasiveness. 18095286 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Data show that EZH2 mRNA expression in circulating epithelial cells represents a promising marker for detecting early metastasis in prostate cancer. 18159594 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Our data disclose a hitherto unexplored link between the putative oncogene EZH2 and the tumor suppressor PSP94, and show that MSMB is silenced by EZH2 in advanced prostate cancer cells. 17237810 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Integrative molecular concept modeling of prostate cancer progression. 17173048 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. 17003774 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer. 17134822 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN A fraction of late-stage tumors contains the gene amplification leading to the overexpression of the EZH2 gene, thus indicating the importance of EZH2 in the progression of prostate cancer 16575874 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Advanced cell- & animal imaging, expression profiling, stable siRNA-gene targeting, and TMAs of experimental and clinical samples indicate that activation of the Ezh2 oncogene-associated PcG pathway plays an essential role in metastatic prostate cancer. 16963837 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN hDAB2IP gene is a target gene of Ezh2 in prostatic epithelium, which provides an underlying mechanism of the down-regulation of hDAB2IP gene in prostate cancer 15817459 2005
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN is overexpressed in hormone-refractory, metastatic prostate cancer; may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression 12374981 2002